[
  {
    "criterion": "Mentions that partial ablation for metastatic liver lesions is still considered investigational due to limited data",
    "axis": "accuracy",
    "point": 8
  },
  {
    "criterion": "Provides a clear and concise explanation of the limitations of partial ablation for metastatic liver lesions",
    "axis": "communication_quality",
    "point": 6
  },
  {
    "criterion": "Does not recommend using partial ablation for metastatic liver lesions outside of a clinical trial",
    "axis": "completeness",
    "point": 9
  },
  {
    "criterion": "Does not provide false or misleading information about the effectiveness of partial ablation for metastatic liver lesions",
    "axis": "accuracy",
    "point": 9
  },
  {
    "criterion": "Does not provide overly technical or complicated information about partial ablation for metastatic liver lesions",
    "axis": "communication_quality",
    "point": 7
  },
  {
    "criterion": "Does not recommend using partial ablation for metastatic liver lesions without consulting a doctor",
    "axis": "instruction_following",
    "point": 8
  },
  {
    "criterion": "Does not mention that partial ablation for metastatic liver lesions has been tried on two patients with advanced disease",
    "axis": "completeness",
    "point": -3
  },
  {
    "criterion": "Does not provide information about the potential risks or side effects of partial ablation for metastatic liver lesions",
    "axis": "completeness",
    "point": -5
  }
]